Hypertension
Conditions
Brief summary
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Interventions
DRUGTreatment A(AD-2321)
AD-2321 Oral Tablet
DRUGTreatment B(AD-2322)
AD-2322 Oral Tablet
DRUGTreatment C(AD-2321+AD-2322)
AD-2321 Oral Tablet+AD-2322 Oral Tablet
Sponsors
Addpharma Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult volunteers aged ≥19 and \<65 years at the time of the screening visit * Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
Exclusion criteria
* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss) | pre-dose (0hour) to 24 hours post-dose on Day 14 | AUCτ,ss |
| Maximum concentration of drug in plasma at steady state (Cmax,ss) | pre-dose (0hour) to 24 hours post-dose on Day 14 | — |
Countries
South Korea
Contacts
Primary ContactSoonKeun Kwon
Outcome results
None listed